NCT02912364View on ClinicalTrials.gov

Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

April 20, 2018

Study Completion Date

April 20, 2018

Conditions
Epilepsy
Interventions
DRUG

Eslicarbazepine

Healthy adults will be titrated onto Eslicarbazepine Acetate (800mg daily) . After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.

DRUG

Carbamazepine

Healthy adults will be titrated onto Carbamazepine (400 mg bid). After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.

Trial Locations (1)

94304

Stanford University, Palo Alto

All Listed Sponsors
collaborator

Sumitomo Pharma America, Inc.

INDUSTRY

lead

Stanford University

OTHER

NCT02912364 - Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults | Biotech Hunter | Biotech Hunter